Objective(1) Review evidence for the use of oral diuretic medications in the management of Ménière’s disease. (2) Analyze therapy‐related hearing and vertigo outcomes.Data SourcesLiterature was obtained through directed searches of MEDLINE, EMBASE, Web of Science, EBSCO Host, Cochrane Reviews, and linked citations through seminal papers. We searched independent electronic databases for articles that reported the use of diuretics in patients with Ménière’s disease.Review MethodsAll articles of level 4 evidence or higher, per the Oxford Centre for Evidence‐Based Medicine, were included with no limit for number of patients, duration of therapy, or follow‐up period. Two independent investigators reviewed the articles for inclusion eligibility. Outcomes were tabulated, including subjective or quantitative measures of hearing, tinnitus, vertigo episode frequency, and medication adverse effects.ResultsNineteen articles were included from 1962 to 2012 from 11 countries. Twelve retrospective case series, 4 randomized controlled trials, 2 case‐control trials, and 1 prospective case series were identified. Six studies investigated isosorbide; 5, hydrochlorothiazide; 2, acetazolamide; 2, chlorthalidone; and 1 each of betahistine, hydrochlorothiazide, chlorthalidone, acetazolamide, hydrochlorothiazide‐triamterene, and nimodipine. Eight (42.1%) studies reported hearing outcomes improvement. Fifteen (79.0%) studies reported vertigo outcomes improvement. Ten (52.6%) studies reported no side effects, and 4 studies (21.1%) reported abdominal discomfort. No significant morbidity or mortality was reported in any study.ConclusionMultiple low evidence–level studies report that oral diuretic therapy may be beneficial in the medical management of Ménière’s disease. Improvement in vertigo episode frequency was consistently reported, with less convincing evidence for improvement in hearing outcomes.

01 Nov 2005·Journal of the American Medical Directors AssociationQ3 · MEDICINE

Combination Drug Therapy

Q3 · MEDICINE

Review

Author: Barbara J. Zarowitz ; Eric G. Tangalos

Caring for the elderly nursing home patient has never been more clinically complex or administratively more troublesome. Patients carry with them a greater burden of disease with increasing frailty and vulnerability. More drugs are being used for more problems. Combination drug therapy (and by this we mean 2 or more drugs in the same pill or capsule) was not common or recommended even just a few years ago. Acceptable combinations for a long time were limited and they were represented by drugs such as hydrochlorothiazide/triamterene (Dyazide; GlaxoSmithKline, Research Triangle Park, NC) and carbidopa/levodopa (Sinemet; Merck & Co, Inc, Whitehouse Station, NJ). Other fixed combinations were generally unavailable because of the significant side effect profiles of individual agents and a relatively poor understanding of drug-drug interactions. A lot has changed in a very short period of time. In an effort to extend patent protection, drug manufacturers are offering a wider array of products in combination dosage forms. Now we have available to us amlodipine/atorvastatin (Caduet; Pfizer US Pharmaceuticals, New York, NY) and ezetimibe/simvastatin (Vytorin; Merck & Co, Inc, and Schering Plough, Kenilworth, NJ) to really push the envelope on the management of cardiovascular disease, affecting blood pressure/angina and lipids at the same time. As we have come to understand the physiologic changes that come with aging (more fat, less muscle mass, and decreased albumin), today’s drugs are designed to be excreted unchanged and with mixed metabolic pathways to avoid total dependence on 1 route of elimination. Ideal pharmacokinetic characteristics of drugs in the elderly are water soluble for ease in absorption, short to intermediate half-life for once daily administration, moderate protein binding, and combined elimination by hepatic and renal routes with an emphasis on glucuronidation and sulfation, rather than oxidative metabolism. Where possible, drug manufacturers are bringing new chemical entities to market that maximize safety and efficacy. Combination drug therapy now offers physicians the opportunity to better comply with OBRA ‘87 and the 9-drug

01 Sep 2005·Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyQ3 · MEDICINE

Hydrochlorothiazide‐Induced Noncardiogenic Pulmonary Edema: An Underrecognized Yet Serious Adverse Drug Reaction

Q3 · MEDICINE

Article

Author: Karen Binkley ; Elizabeth J. Phillips ; Sherali A. Rahim ; Sandra R. Knowles ; Gavin A. Wong ; Neil H. Shear

Noncardiogenic pulmonary edema is a rare but potentially life‐threatening complication of hydrochlorothiazide therapy. We describe three patients who developed this serious adverse reaction. A 64‐year‐old woman developed dypsnea and hypotension within 60 minutes of taking a single dose of hydrochlorothiazide 25 mg. She was admitted to the critical care unit with acute respiratory failure and subsequent multiple‐organ dysfunction. The second patient was a 56‐year‐old woman who experienced sudden onset of shortness of breath that developed 10 minutes after taking a single dose of hydrochlorothiazide 25 mg. The third was a 59‐year‐old woman who developed sudden onset of shortness of breath, nausea, vomiting, and diarrhea after her first dose of hydrochlorothiazide‐triamterene. All three women had a history of a similar, albeit minor, reaction to a thiazide diuretic. Review of the literature identified 36 additional cases of noncardiogenic pulmonary edema after thiazide use. The patients developed symptoms 10–150 minutes after ingestion of hydrochlorothiazide or another thiazide. Symptoms can occur on first exposure to the drug or in patients taking the drug intermittently. Of interest, 90% of documented cases occurred in women. With the increasing use of thiazide diuretics in the treatment of hypertension, clinicians need to be aware of the possible association of these drugs with the development of noncardiogenic pulmonary edema.

100 Deals associated with Hydrochlorothiazide/Triamterene

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C03EA01	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Edema	US	Aurobindo Pharma USA, Inc.	22 Oct 1984
Hypertension	US	Aurobindo Pharma USA, Inc.	22 Oct 1984

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2013	Not Applicable	Diabetes Insipidus, Nephrogenic	1	Lamivudine	nvyloxlouq(tcucsfdgbx) = A diagnosis of acute nephrogenic diabetes insipidus (NDI) was made vxjhzbeobx (ksslurfzvp ) View more	Positive	05 Nov 2013
				Maxzide
ASN2012	Not Applicable	Hypokalemia \| Acute Kidney Injury	-	Maxzide	(plksueyxlm) = slomtuqyzm xvfalisfbz (sqkpncubeq )	Negative	30 Oct 2012
				Hydrochlorothiazide (HCTZ)	(plksueyxlm) = keqglgjlxw xvfalisfbz (sqkpncubeq )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hydrochlorothiazide/Triamterene

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation